Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Luminex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LMNX's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: LMNX underperformed the US Life Sciences industry which returned 45.1% over the past year.
Return vs Market: LMNX underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Luminex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StWe Think Luminex (NASDAQ:LMNX) Can Manage Its Debt With Ease
2 weeks ago | Simply Wall StIs Luminex Corporation (NASDAQ:LMNX) At Risk Of Cutting Its Dividend?
1 month ago | Simply Wall StDividend Investors: Don't Be Too Quick To Buy Luminex Corporation (NASDAQ:LMNX) For Its Upcoming Dividend
Is Luminex undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LMNX ($21.24) is trading below our estimate of fair value ($21.63)
Significantly Below Fair Value: LMNX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: LMNX is poor value based on its PE Ratio (85x) compared to the US Life Sciences industry average (44.6x).
PE vs Market: LMNX is poor value based on its PE Ratio (85x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: LMNX is poor value based on its PEG Ratio (9.3x)
Price to Book Ratio
PB vs Industry: LMNX is good value based on its PB Ratio (1.9x) compared to the US Life Sciences industry average (6.9x).
How is Luminex forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LMNX's forecast earnings growth (9.1% per year) is above the savings rate (2.2%).
Earnings vs Market: LMNX's earnings (9.1% per year) are forecast to grow slower than the US market (22% per year).
High Growth Earnings: LMNX's earnings are forecast to grow, but not significantly.
Revenue vs Market: LMNX's revenue (8.7% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: LMNX's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LMNX's Return on Equity is forecast to be high in 3 years time
How has Luminex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LMNX has high quality earnings.
Growing Profit Margin: LMNX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: LMNX's earnings have declined by 38.7% per year over the past 5 years.
Accelerating Growth: LMNX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: LMNX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (14.9%).
Return on Equity
High ROE: LMNX's Return on Equity (2.2%) is considered low.
How is Luminex's financial position?
Financial Position Analysis
Short Term Liabilities: LMNX's short term assets ($454.9M) exceed its short term liabilities ($62.8M).
Long Term Liabilities: LMNX's short term assets ($454.9M) exceed its long term liabilities ($217.1M).
Debt to Equity History and Analysis
Debt Level: LMNX's debt to equity ratio (39.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LMNX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: LMNX's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: LMNX's interest payments on its debt are well covered by EBIT (7.7x coverage).
What is Luminex current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LMNX's dividend (1.69%) is higher than the bottom 25% of dividend payers in the US market (1.65%).
High Dividend: LMNX's dividend (1.69%) is low compared to the top 25% of dividend payers in the US market (4.67%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, LMNX has been paying a dividend for less than 10 years.
Growing Dividend: LMNX's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (144.1%), LMNX's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Homi Shamir (66 yo)
Mr. Nachum Shamir, also known as Homi, has been Chief Executive Officer and President of Luminex Corporation since October 15, 2014. Mr. Shamir served as Chief Executive Officer and President of Given at I ...
CEO Compensation Analysis
Compensation vs Market: Homi's total compensation ($USD3.36M) is about average for companies of similar size in the US market ($USD2.90M).
Compensation vs Earnings: Homi's compensation has been consistent with company performance over the past year.
|CFO, Senior VP of Finance & Treasurer||18yrs||US$1.11m||0.54% |
|Senior VP||5.58yrs||US$909.31k||0.072% |
|Senior Vice President of Global Sales & Customer Operations||3.92yrs||US$900.02k||0.12% |
|Senior Vice President of Global Manufacturing & Quality||5.58yrs||US$884.88k||0.074% |
|Vice President of Accounting||12.83yrs||no data||no data|
|Senior Director of Investor Relations||no data||no data||no data|
|Senior Vice President of Global Marketing||5yrs||no data||0.073% |
|Senior Vice President of Human Resources||5.75yrs||US$749.50k||0.073% |
|Senior Vice President of Research & Development||2.75yrs||no data||0.075% |
Experienced Management: LMNX's management team is seasoned and experienced (5.6 years average tenure).
|Independent Director||23.83yrs||US$178.98k||0.35% |
|Independent Director||17.42yrs||US$198.94k||0.072% |
|Lead Independent Director||0.17yr||US$178.98k||0.13% |
|Independent Director||16.42yrs||US$178.93k||0.19% |
|Independent Director||1.08yrs||US$90.46k||0.015% |
|Independent Director||1.83yrs||US$238.43k||0.042% |
|Independent Director||4.58yrs||US$148.97k||0.072% |
Experienced Board: LMNX's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Luminex Corporation's company bio, employee growth, exchange listings and data sources
- Name: Luminex Corporation
- Ticker: LMNX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$984.753m
- Shares outstanding: 46.36m
- Website: https://www.luminexcorp.com
Number of Employees
- Luminex Corporation
- 12212 Technology Boulevard
- Suite 130
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LMNX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2000|
|LMX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2000|
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include L ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/23 00:53|
|End of Day Share Price||2020/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.